{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"600"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"RP2D was determined by dose escalating monotherapy groups.","groups":[{"description":"Mezagitamab SC, at escalating doses ranging from 45 mg to 1200 mg once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG000","title":"Phase 1 Dose Escalation Cohort: Mezagitamab"}],"paramType":"NUMBER","populationDescription":"DLT-evaluable analysis set included participants who received all Cycle 1 doses of mezagitamab and completed Cycle 1 procedures or experienced a DLT in Cycle 1.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)","title":"Phase 1: RP2D of TAK-079","type":"SECONDARY","unitOfMeasure":"mg"}